Skip to main content
For COVID-19 vaccine updates, please
review our information guide
and
sign up for Connect
. Continue your routine care with us by scheduling an
in-person appointment
or
Video Visit
.
Enter the terms you wish to search for.
Select Search Option
This Site
All WCM Sites
Directory
Menu
Weill Cornell Medicine
Care
Discover
Teach
Myeloma Center
Explore this Website
Home
About Us
Toggle menu options
Our Team
Patient Testimonials
News
For Patients
Toggle menu options
Health Information Library and Patient Resources
Support Groups and Helpful Links
Frequently Asked Questions
Your First Visit
Toggle menu options
Self-Referral
Lab Work/Procedures
Referring Physicians
Toggle menu options
Refer a Patient
Research and Clinical Trials
Toggle menu options
Basic and Translational Research
Bibliography
Contact Us
Weill Cornell Medicine
Care
Discover
Teach
Home
About Us
For Patients
Referring Physicians
Research and Clinical Trials
Contact Us
Home
Bibliography
Bibliography
Basic and Translational Research
Bibliography
Bibliography
Found 9 results
Author
[
Title
]
Type
Year
Filters:
Author
is
Chen-Kiang, Selina
[Clear All Filters]
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
A
Mark T
,
Jayabalan D
,
Coleman M
,
Pearse RN
,
Y Wang L
,
Lent R
,
Christos PJ
,
Lee JW
,
Agrawal YP
,
Matthew S
et al.
. 2008.
Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma.
.
Br J Haematol. 143(5):654-60.
B
Niesvizky R
,
Jayabalan DS
,
Christos PJ
,
Furst JR
,
Naib T
,
Ely S
,
Jalbrzikowski J
,
Pearse RN
,
Zafar F
,
Pekle K
et al.
. 2008.
BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.
.
Blood. 111(3):1101-9.
C
Ely S
,
Forsberg P
,
Ouansafi I
,
Rossi A
,
Modin A
,
Pearse R
,
Pekle K
,
Perry A
,
Coleman M
,
Jayabalan D
et al.
. 2017.
Cellular Proliferation by Multiplex Immunohistochemistry Identifies High-Risk Multiple Myeloma in Newly Diagnosed, Treatment-Naive Patients.
.
Clin Lymphoma Myeloma Leuk. 17(12):825-833.
Gay F
,
S Rajkumar V
,
Coleman M
,
Kumar S
,
Mark T
,
Dispenzieri A
,
Pearse R
,
Gertz MA
,
Leonard J
,
Lacy MQ
et al.
. 2010.
Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma.
.
Am J Hematol. 85(9):664-9.
G
Wei X
,
M Calvo-Vidal N
,
Chen S
,
Wu G
,
Revuelta MV
,
Sun J
,
Zhang J
,
Walsh MF
,
Nichols KE
,
Joseph V
et al.
. 2018.
Germline Lysine-Specific Demethylase 1 () Mutations Confer Susceptibility to Multiple Myeloma.
.
Cancer Res. 78(10):2747-2759.
L
Niesvizky R
,
Naib T
,
Christos PJ
,
Jayabalan D
,
Furst JR
,
Jalbrzikowski J
,
Zafar F
,
Mark T
,
Lent R
,
Pearse RN
et al.
. 2007.
Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy.
.
Br J Haematol. 138(5):640-3.
P
Niesvizky R
,
Badros AZ
,
Costa LJ
,
Ely SA
,
Singhal SB
,
Stadtmauer EA
,
Haideri NA
,
Yacoub A
,
Hess G
,
Lentzsch S
et al.
. 2015.
Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.
.
Leuk Lymphoma. 56(12):3320-8.
Niesvizky R
,
Ely S
,
Mark T
,
Aggarwal S
,
Gabrilove JL
,
Wright JJ
,
Chen-Kiang S
,
Sparano JA
. 2011.
Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma.
.
Cancer. 117(2):336-42.
T
Mark TM
,
Bowman IA
,
Rossi AC
,
Shah M
,
Rodriguez M
,
Quinn R
,
Pearse RN
,
Zafar F
,
Pekle K
,
Jayabalan D
et al.
. 2014.
Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma.
.
Leuk Lymphoma. 55(12):2842-9.